Europe recommends ban on common plasma substitute

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3942 (Published 17 June 2013)
Cite this as: BMJ 2013;346:f3942

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jacqui Wise
  1. 1London

The European Medicine Agency has suspended the marketing authorisation for infusion solutions containing hydroxyethyl starch, saying that their benefits no longer outweigh their risks. In the United Kingdom the Medicines Healthcare Products Regulatory Agency is reviewing the evidence and will make a decision next week.

Starch drips are mainly used to replace lost blood volume in hypovolaemia and hypovolaemic shock. They are used in critically ill patients such as those with sepsis, burn, or trauma injuries and patients …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL